Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Fineline Cube Mar 26, 2026
Company Deals

MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia

Fineline Cube Mar 26, 2026
Company Deals

Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification

Fineline Cube Mar 26, 2026
Company Deals

Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market

Fineline Cube Mar 26, 2026
Company Deals

Insilico Medicine Expands AI Collaboration with Tenacia Bio – $94.75M Deal Targets CNS Drug Discovery with Blood-Brain Barrier Penetration

Fineline Cube Mar 26, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy

Fineline Cube Mar 26, 2026
Company Drug

United Laboratories Novo Nordisk Report Positive Phase II Data for UBT251 – Triple GLP-1/GIP/GCG Agonist Achieves 19.7% Weight Los

Fineline Cube Mar 26, 2026
Drug

Roche’s Rozlytrek Wins NMPA Approval for NTRK Fusion Gene-Positive Tumors

Fineline Cube Jul 29, 2022

Swiss pharmaceutical giant Roche announced that it has received marketing approval from the National Medical...

Company Drug

Kira Pharmaceuticals’ KP104 Receives Orphan Drug Designation for PNH Treatment

Fineline Cube Jul 29, 2022

Sino-US biotech Kira Pharmaceuticals announced that it has received an Orphan Drug Designation (ODD) from...

Policy / Regulatory R&D

Shenzhen Unveils Measures to Boost Biomedical and Medical Device Industries

Fineline Cube Jul 29, 2022

Shenzhen’s municipal Development and Reform Commission has released a series of measures to promote the...

Company

Merck’s Q2 Sales Surge 31% to USD 14.6B, Led by Keytruda and China Growth

Fineline Cube Jul 29, 2022

US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) reported Q2 2022 global sales of USD...

Company Drug

Takeda’s Alunbrig Prescribed in China for ALK+ NSCLC Treatment

Fineline Cube Jul 29, 2022

Japan-based Takeda Pharmaceutical Co., Ltd (TYO: 4502) announced that its lung cancer therapy Alunbrig (brigatinib)...

Company Deals

Cosmo Pharma’s Winlevi Cream Secures Greater China Licensing Deal with 3SBio

Fineline Cube Jul 29, 2022

Ireland-based Cosmo Pharmaceuticals NV (SWX: COPN) and China’s 3SBio Inc. (HKG: 1530) have signed a...

Company R&D

PerkinElmer and SCUT Launch Joint Translational Medicine Center

Fineline Cube Jul 29, 2022

US-based PerkinElmer and China’s South China University of Technology (SCUT) have officially launched their joint...

Policy / Regulatory

Sun Pharma’s Bicalutamide Supply Suspended in Multiple Chinese Regions

Fineline Cube Jul 28, 2022

India-based Sun Pharma has suspended the supply of its bicalutamide to Beijing, Tianjin, Jilin, Shanghai,...

Company Drug

MabPharm’s CMAB015 Biosimilar Receives NMPA Approval for Clinical Study

Fineline Cube Jul 28, 2022

Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received...

Company Deals

CSPC Jushi Biopharm’s SYSA1801 ADC Secures Licensing Deal with Elevation Oncology

Fineline Cube Jul 28, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary, CSPC Jushi Biopharmaceutical Co.,...

Policy / Regulatory

CDE Releases 61st Batch of Generic Reference Preparations, 34 New Specs Added

Fineline Cube Jul 28, 2022

The Center for Drug Evaluation (CDE) has released the 61st batch of chemical generic reference...

Company

Immunochina Pharmaceuticals Secures CAR-T Production License in Beijing

Fineline Cube Jul 28, 2022

Beijing-based Immunochina Pharmaceuticals has obtained a Drug Production License for its chimeric antigen receptor (CAR)...

Company Deals

Kolo Medical Raises RMB 100M in Series B2 to Launch High-Frequency Ultrasound Imaging System

Fineline Cube Jul 28, 2022

Suzhou-based Kolo Medical Inc., a leader in next-generation semiconductor ultrasound CMUT (Capacitive Micromachined Ultrasonic Transducer)...

Company Drug

Nestle Launches China’s First Cancer-Focused FSMP Product Oral Impact Su Yi Su

Fineline Cube Jul 28, 2022

Switzerland-based Nestle announced the launch of China’s first “foods for special medical purposes” (FSMP) product...

Company Digital

Sanofi’s Hornstein Sees China’s Online Hospitals Boosting Digital Health Strategy

Fineline Cube Jul 28, 2022

Sanofi’s outgoing China market president, Pius Hornstein, expressed confidence in the potential of China’s online...

Company Drug

Nuance Pharma Initiates Phase I Study for Ketorolac IV Infusion (NTM-001)

Fineline Cube Jul 27, 2022

China-based Nuance Pharma announced the initiation of subject enrollment and the first drug infusion in...

Company Drug

Henlius Biotech’s HanBeiTai Biosimilar of Avastin Accepted for CDE Review

Fineline Cube Jul 27, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the Center for Drug Evaluation (CDE) has...

Company Deals

CStone Pharmaceuticals and Kindstar Global Partner on Blood Tumor Precision Diagnosis and Treatment

Fineline Cube Jul 27, 2022

China-based CStone Pharmaceuticals (HKG: 2616) announced a strategic collaboration with compatriot firm Kindstar Global (HKG:...

Company Deals

Wanbangde Pharmaceutical to Acquire Consun Pharma Shares in RMB 2.2B Deal

Fineline Cube Jul 27, 2022

China-based Wanbangde Pharmaceutical Group has entered into a non-legally binding letter of intent with Consun...

Company Drug

Brii Biosciences’ COVID-19 Antibody Cocktail Effective Against Omicron BA.4/5 and BA.2.12.1

Fineline Cube Jul 27, 2022

China-based Brii Biosciences Ltd (HKG: 2137) announced that its anti-COVID-19 antibody cocktail amubarvimab + romlusevimab...

Posts pagination

1 … 619 620 621 … 641

Recent updates

  • China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years
  • Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%
  • GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market
  • Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy
  • Boehringer Ingelheim 2024 Revenue EUR 27.8B – Jardiance Drives 8.7% Growth, R&D Intensity Hits 22.9%
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Company

Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%

Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Company Drug

Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.